![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease
To the Editor A recent article reported that zerlasiran was well tolerated, with a time-averaged percent change in lipoprotein(a) concentration of more than 80% from baseline to 36 weeks in patients with atherosclerotic cardiovascular disease. However, we have some concerns about this study.
To the Editor A recent article reported that zerlasiran was well tolerated, with a time-averaged percent change in lipoprotein(a) concentration of more than 80% from baseline to 36 weeks in patients with atherosclerotic cardiovascular disease. However, we have some concerns about this study.
